JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB203061

Anti-Osteoprotegerin antibody

Be the first to review this product! Submit a review

|

(16 Publications)

Rabbit Polyclonal Osteoprotegerin antibody. Suitable for WB and reacts with Human samples. Cited in 16 publications. Immunogen corresponding to Synthetic Peptide within Mouse Tnfrsf11b aa 200-300 conjugated to Keyhole Limpet Haemocyanin.

View Alternative Names

OCIF, OPG, TNFRSF11B, Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin

1 Images
Western blot - Anti-Osteoprotegerin antibody (AB203061)
  • WB

Supplier Data

Western blot - Anti-Osteoprotegerin antibody (AB203061)

All lanes:

Western blot - Anti-Osteoprotegerin antibody (ab203061) at 1/1000 dilution

Lane 1:

Human Raji cell lysate

Lane 2:

Human U251 cell lysate

Secondary

All lanes:

Conjugated Secondary at 1/20000 dilution

Predicted band size: 46 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Mouse Tnfrsf11b aa 200-300 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

O08712

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/300", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.
Biological function summary

OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.

Pathways

OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.

OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
See full target information TNFRSF11B

Publications (16)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in bioengineering and biotechnology 13:1555983 PubMed40599407

2025

Distribution and metabolism of iPSC-MSCs in the joint cavity of an osteoarthritis rat model.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoyang Yuan,Xulei Wang,Tianxi Du,Feng Zhang,Gang Cheng,Kang Wang,Haochen Xu,Pingting Yang,Yan Chang,Wei Wei,Peng He,Shangxue Yan

Journal of clinical medicine 14: PubMed39941567

2025

Adjunctive Treatment Effect of Non-Thermal Atmospheric Pressure Plasma in Periodontitis-Induced Rats.

Applications

Unspecified application

Species

Unspecified reactive species

Hee-Young Choi,Hyun-Joo Kim,Ju-Youn Lee,Ji-Young Joo

BMC oral health 25:78 PubMed39819670

2025

Investigation of the preventive effect of methylsulfonylmethane on alveolar bone loss and oxidative stress in a rat model of periodontitis.

Applications

Unspecified application

Species

Unspecified reactive species

Melek Beder,Hatice Yemenoglu,Semih Alperen Bostan,Oğuz Kose,Sibel Mataracı Karakas,Tolga Mercantepe,Adnan Yılmaz,Levent Tumkaya

Progress in orthodontics 25:45 PubMed39581932

2024

Effect of anti-sclerostin antibody on orthodontic tooth movement in ovariectomized rats.

Applications

Unspecified application

Species

Unspecified reactive species

Hyunna Ahn,Wonse Park,Sung-Hwan Choi,Namki Hong,Jisun Huh,Seoyeon Jung

Signal transduction and targeted therapy 8:280 PubMed37500654

2023

Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms.

Applications

Unspecified application

Species

Unspecified reactive species

Na Jia,Yunzhen Gao,Min Li,Yi Liang,Yuwen Li,Yunzhu Lin,Shiqi Huang,Qing Lin,Xun Sun,Qin He,Yuqin Yao,Ben Zhang,Zhirong Zhang,Ling Zhang

Pharmaceutical biology 61:391-403 PubMed36740874

2023

Regulation of bone and fat balance by Fructus Ligustri Lucidi in ovariectomized mice.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoyan Qin,Qiu Wei,Ran An,Yun Yang,Mingqi Cai,Xiaoling Han,Haoping Mao,Xiumei Gao

Journal of cellular and molecular medicine 26:4032-4047 PubMed35726597

2022

Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Yihao Tian,Jian Ming

Frontiers in pharmacology 12:710169 PubMed34552485

2021

Salvianolate Ameliorates Osteopenia and Improves Bone Quality in Prednisone-Treated Rheumatoid Arthritis Rats by Regulating RANKL/RANK/OPG Signaling.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Gao,Qingyun Wu,Xinle Zhang,Jia Tian,Dahong Liang,Yalin Min,Jiaqi Lu,Xuemei Zhang,Liao Cui,Bilian Xu,Yanzhi Liu

International journal of molecular sciences 22: PubMed34502380

2021

Piezoelectric Microvibration Mitigates Estrogen Loss-Induced Osteoporosis and Promotes Piezo1, MicroRNA-29a, and Wnt3a Signaling in Osteoblasts.

Applications

Unspecified application

Species

Unspecified reactive species

Re-Wen Wu,Wei-Shiung Lian,Yu-Shan Chen,Jih-Yang Ko,Shao-Yu Wang,Holger Jahr,Feng-Sheng Wang

Annals of translational medicine 9:768 PubMed34268381

2021

Diabetes mellitus accelerates the progression of osteoarthritis in streptozotocin-induced diabetic mice by deteriorating bone microarchitecture, bone mineral composition, and bone strength of subchondral bone.

Applications

Unspecified application

Species

Unspecified reactive species

Hua-Jun Wang,Hugo Giambini,Ji-Wen Chen,Qiu-Shi Wang,Hui-Ge Hou,Si-Min Luo,Jun-Yuan Chen,Teng-Feng Zhuang,Yuan-Feng Chen,Ting-Ting Wu,Zhen-Gang Zha,You-Jie Liu,Xiao-Fei Zheng
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com